» Articles » PMID: 35198656

Clinical and CT Patterns to Predict EGFR Mutation in Patients with Non-small Cell Lung Cancer: A Systematic Literature Review and Meta-analysis

Abstract

Purpose: This study aims to determine if the presence of specific clinical and computed tomography (CT) patterns are associated with epidermal growth factor receptor (EGFR) mutation in patients with non-small cell lung cancer.

Methods: A systematic literature review and meta-analysis was carried out in 6 databases between January 2002 and July 2021. The relationship between clinical and CT patterns to detect EGFR mutation was measured and pooled using odds ratios (OR). These results were used to build several mathematical models to predict EGFR mutation.

Results: 34 retrospective diagnostic accuracy studies met the inclusion and exclusion criteria. The results showed that ground-glass opacities (GGO) have an OR of 1.86 (95%CI 1.34 -2.57), air bronchogram OR 1.60 (95%CI 1.38 - 1.85), vascular convergence OR 1.39 (95%CI 1.12 - 1.74), pleural retraction OR 1.99 (95%CI 1.72 - 2.31), spiculation OR 1.42 (95%CI 1.19 - 1.70), cavitation OR 0.70 (95%CI 0.57 - 0.86), early disease stage OR 1.58 (95%CI 1.14 - 2.18), non-smoker status OR 2.79 (95%CI 2.34 - 3.31), female gender OR 2.33 (95%CI 1.97 - 2.75). A mathematical model was built, including all clinical and CT patterns assessed, showing an area under the curve (AUC) of 0.81.

Conclusions: GGO, air bronchogram, vascular convergence, pleural retraction, spiculated margins, early disease stage, female gender, and non-smoking status are significant risk factors for EGFR mutation. At the same time, cavitation is a protective factor for EGFR mutation. The mathematical model built acts as a good predictor for EGFR mutation in patients with lung adenocarcinoma.

Citing Articles

Distinguishing EGFR mutant subtypes in stage IA non-small cell lung cancer using the presence status of ground glass opacity and final histologic classification: a systematic review and meta-analysis.

Qiu J, Ma Z, Li R, Qu C, Wang K, Liu B Front Med (Lausanne). 2023; 10:1268846.

PMID: 38126071 PMC: 10731050. DOI: 10.3389/fmed.2023.1268846.


Pleural metastasis of pulmonary adenocarcinoma mimicking diffuse mesothelioma: A case report and literature study.

Shalahuddin E, Hayati F Radiol Case Rep. 2022; 18(3):818-823.

PMID: 36582758 PMC: 9793177. DOI: 10.1016/j.radcr.2022.11.049.


Association between squamous cell carcinoma antigen level and EGFR mutation status in Chinese lung adenocarcinoma patients.

Zhang S, Gao J, Niu R, Ye J, Ma J, Jiang L J Clin Lab Anal. 2022; 36(9):e24613.

PMID: 35838003 PMC: 9459300. DOI: 10.1002/jcla.24613.


Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients With Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis.

Herrera Ortiz A, Garland M, Almarie B Cureus. 2022; 14(5):e25446.

PMID: 35774697 PMC: 9238903. DOI: 10.7759/cureus.25446.


Response to: A commentary on "Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis".

Herrera Ortiz A, Camacho T, Vasquez A, Herazo V, Neira J, Yepes M Eur J Radiol Open. 2022; 9:100409.

PMID: 35242890 PMC: 8885605. DOI: 10.1016/j.ejro.2022.100409.


References
1.
Tu W, Sun G, Fan L, Wang Y, Xia Y, Guan Y . Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. Lung Cancer. 2019; 132:28-35. DOI: 10.1016/j.lungcan.2019.03.025. View

2.
Qin X, Gu X, Lu Y, Zhou W . EGFR-TKI-sensitive mutations in lung carcinomas: are they related to clinical features and CT findings?. Cancer Manag Res. 2018; 10:4019-4027. PMC: 6173510. DOI: 10.2147/CMAR.S174623. View

3.
Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y . Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012; 18(7):1947-53. PMC: 3319848. DOI: 10.1158/1078-0432.CCR-11-2511. View

4.
Suh Y, Lee H, Kim Y, Kim K, Kim H, Jeon Y . Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study. Lung Cancer. 2018; 123:52-59. DOI: 10.1016/j.lungcan.2018.06.030. View

5.
Zheng J, Yu Z, Xiao W, Zhao J, Sun K, Wang B . Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol. 2015; 25(5):1257-66. DOI: 10.1007/s00330-014-3516-z. View